Most physicians leave institutional medicine assuming their clinical judgment will carry the practice.

What carries a practice is infrastructure you probably haven't built yet. The ability to source reliably. Price transparently. Deliver consistently. Scale without breaking what already works.

Peptides and hormones expose this faster than any other category.

The clinical decision is the easy part.

You already know when testosterone makes sense. When BPC-157 might help. When thyroid optimization matters.

The hard part is everything that happens after.

Can you source without variability between batches? Can you price without explaining markups? Can you deliver without patients waiting three weeks? Can you add volume without your current team collapsing?

Most practices stall here. Not because the physician made a bad clinical call. Because the practice was never built to handle operational complexity at scale.

Institutional medicine hides infrastructure.

Pharmacy handles sourcing. Billing handles pricing. Someone else manages fulfillment. You make clinical decisions. The system absorbs everything else.

When you leave, you inherit all of it.

Physicians who add peptides and hormones without building operational capacity end up in one of three positions:

They limit volume to what they can personally manage. Revenue stays low.

They scale quickly and create bottlenecks that degrade quality. Patients notice.

They outsource fulfillment to a partner who controls pricing, margins, and patient experience. Independence disappears.

None of these outcomes happen because of bad clinical judgment. They happen because scaling modern therapies requires infrastructure most practices don't build upfront.

The pattern repeats quietly.

A practice adds GLP-1s or peptides. Demand increases. The physician assumes hiring another provider solves the constraint.

The constraint was never clinical capacity. It was operational capacity. Sourcing. Pricing. Fulfillment. Communication. The ability to deliver the same experience at higher volume without manual intervention.

Practices that work at 20 patients per month break at 200. Not because the clinical model was wrong. Because the infrastructure wasn't designed to scale.

Speed reveals structure.

Adding peptides or hormones and then slowing down to rethink workflows means the infrastructure wasn't ready.

Fulfillment that depends on personally managing pharmacy relationships is fragile.

Pricing that requires justification per patient doesn't scale.

The question isn't whether peptides and hormones improve outcomes. The question is whether your practice can deliver them repeatedly, predictably, and profitably without you becoming the bottleneck.

Clinical expertise opened the door.

Infrastructure determines whether you can walk through it.

What's available, what's protected, and why clinicians are prescribing research compounds in a post-ban landscape

The FDA's peptide restrictions didn't eliminate access to peptides.

They reorganized the map.

What used to be straightforward (prescribe, compound, deliver) now requires understanding distinctions most clinicians never had to consider.

Research versus compounded. 503A versus 503B. Category 2 versus Category 1.

Practices that understand the current landscape are scaling. Practices that don't are limiting what they offer, taking on unexamined risk, or abandoning peptides entirely.

What happened in September 2023

The FDA updated its interim policy on bulk drug substances for compounding under Section 503A. Several peptides moved into Category 2, deemed to present significant safety risks.

Category 2 placement means compounding pharmacies cannot legally produce these substances. The stated rationale: insufficient evidence of safety and efficacy, risk of immunogenicity, peptide-related impurities, limited safety data.

The banned list included compounds clinics had been using for years. BPC-157. Thymosin Alpha-1. TB-500. CJC-1295. Ipamorelin. AOD-9604. DSIP. Epithalon. Melanotan II. Selank. Semax. KPV. LL-37.

The restriction didn't make these peptides illegal to prescribe. It made them unavailable through traditional compounding channels.

What's actually available through 503A

Currently available (as of January 2025):

GLP-1 agonists: Semaglutide and tirzepatide, but enforcement discretion periods are ending and compounding rules are tightening.

Growth hormone peptides: Sermorelin.

Other: NAD+. GHK-Cu (topical only, not injectable).

Practices building around available 503A peptides have regulatory clarity and predictable sourcing. The tradeoff: limited selection.

What's banned (Category 2)

Cannot be legally compounded by 503A or 503B facilities:

BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, DSIP, Epithalon, Melanotan II, KPV, Selank, Semax, LL-37, MOTs-C, GHK-Cu (injectable).

Also: Tesamorelin was reclassified as a biologic in 2020. 503A pharmacies cannot compound it.

Compounding pharmacies that produce these face FDA enforcement action.

Why clinicians are prescribing research peptides

The compounds on the Category 2 list didn't stop being clinically relevant when the FDA restricted compounding access.

Some clinicians decided the clinical utility outweighed the loss of compounding infrastructure. They found another route: research peptide suppliers.

Research peptides are sold with disclaimers: "Not for human consumption." "For research purposes only." "Not evaluated by the FDA."

The legal framework is thin. The quality control is variable. The regulatory protection is minimal.

Clinicians who prescribe research peptides are making a calculated decision. They believe the clinical benefit justifies the sourcing risk. They trust their supplier's manufacturing standards. They accept that they're operating outside traditional frameworks.

It's a tradeoff.

The question is whether the clinician understands what they're trading.

What protection actually looks like

503A compounding offers state board oversight, established quality standards, predictable sourcing, regulatory clarity, and certificates of analysis from FDA-registered manufacturers.

Research peptide sourcing offers access to banned compounds, often lower cost, faster availability, but no regulatory framework, variable quality control, legal ambiguity, and enforcement risk.

Practices using research peptides aren't automatically operating unsafely. But they're absorbing risk that 503A infrastructure was designed to distribute across regulatory systems, state boards, and compounding standards.

When something goes wrong with a 503A peptide, the system has mechanisms. When something goes wrong with a research peptide, the clinician is exposed.

How practices are navigating this

Three patterns have emerged:

Pattern 1: Stay within 503A boundaries. Build protocols around sermorelin, semaglutide, tirzepatide, NAD+. Regulatory clarity, limited selection.

Pattern 2: Use 503A for baseline protocols, source research peptides for specific clinical situations. Vet suppliers carefully. Document decisions. Broader access, thinner protection.

Pattern 3: Source everything outside compounding frameworks. Compete on access to compounds others won't touch. Minimal regulatory protection, maximum exposure.

Different risk profiles. Different infrastructure requirements. Different scaling limitations.

Practices that understand which pattern they're running can plan accordingly. Practices that don't discover their constraints when demand increases, when quality issues surface, or when enforcement begins.

What determines outcomes

The peptide landscape isn't about what's clinically optimal.

It's about what infrastructure you can build around.

Can you source reliably within 503A constraints? Regulatory clarity, limited selection.

Can you vet research suppliers and absorb sourcing risk? Broader access, thinner protection.

Can you build hybrid infrastructure managing both? Different sourcing channels, quality standards, compliance frameworks simultaneously.

Most practices assume the clinical decision determines the peptide strategy.

The infrastructure determines the peptide strategy.

Clinical expertise identifies the compound. Infrastructure determines whether you can deliver it repeatedly, safely, and profitably without regulatory exposure.

The restrictions didn't eliminate peptides. They revealed which practices understood the system and which practices were relying on infrastructure they never had to build themselves.

I've spent the past decade building and scaling operations across clinics, telehealth platforms, and compounding pharmacies. I've seen practices succeed at 20 patients per month and break at 200. I've watched regulatory shifts reorganize entire markets overnight. I've built the infrastructure that determines whether modern therapies scale or stall.

This newsletter is about understanding how the system actually functions, where friction hides, and why some approaches compound over time while others don't.

If you're building, running, or participating in modern health in any real way, this layer matters more than most people realize.

Until next time,